{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:24:15Z","timestamp":1777695855104,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejmech.2020.112658","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T20:53:53Z","timestamp":1595364833000},"page":"112658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design, synthesis and in\u00a0vitro cell-free\/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway"],"prefix":"10.1016","volume":"204","author":[{"given":"Ahmed H.","family":"Elmenoufy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8299-1976","authenticated-orcid":false,"given":"Francesco","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-6326","authenticated-orcid":false,"given":"David","family":"Jay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feridoun","family":"Karimi-Busheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier M.","family":"Soueidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajam S.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Ciniero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9976-0429","authenticated-orcid":false,"given":"Jack A.","family":"Tuszynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-1425","authenticated-orcid":false,"given":"Michael","family":"Weinfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7419-2314","authenticated-orcid":false,"given":"Frederick G.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112658_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.gene.2015.06.026","article-title":"The ERCC1 and ERCC4 (XPF) genes and gene products","volume":"569","author":"Manandhar","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2020.112658_bib2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/emboj.2009.49","article-title":"Coordination of dual incision and repair synthesis in human nucleotide excision repair","volume":"28","author":"Staresincic","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2020.112658_bib3","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1128\/MCB.00293-08","article-title":"ERCC1-XPF endonuclease facilitates DNA double-strand break repair","volume":"28","author":"Ahmad","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112658_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","article-title":"Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance","volume":"2","author":"McHugh","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2020.112658_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/mutage\/13.6.595","article-title":"Sensitivity of group F xeroderma pigmentosum cells to UV and mitomycin C relative to levels of XPF and ERCC1 overexpression","volume":"13","author":"Yagi","year":"1998","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ejmech.2020.112658_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0092-8674(00)80155-5","article-title":"Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease","volume":"86","author":"Sijbers","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112658_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.20517\/2394-4722.2016.52","article-title":"ERCC1 expression in patients with colorectal cancer: a pilot study","volume":"12","author":"Gajjar","year":"2016","journal-title":"J.\u00a0Canc. Metastasis Treat."},{"key":"10.1016\/j.ejmech.2020.112658_bib8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.str.2005.08.014","article-title":"The structure of the human ERCC1\/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair","volume":"13","author":"Tripsianes","year":"2005","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2020.112658_bib9","first-page":"10","article-title":"Targeting the DNA repair endonuclease ERCC1-XPF with green tea polyphenol epigallocatechin-3-Gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells","author":"Heyza","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2020.112658_bib10","doi-asserted-by":"crossref","first-page":"75104","DOI":"10.18632\/oncotarget.12072","article-title":"Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells","volume":"7","author":"Arora","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112658_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.112.082347","article-title":"Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells","volume":"84","author":"Jordheim","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112658_bib12","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1016\/j.bmcl.2015.08.024","article-title":"N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1\u2013XPF","volume":"25","author":"Chapman","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112658_bib13","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.bmcl.2015.08.031","article-title":"Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF","volume":"25","author":"Chapman","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112658_bib14","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1093\/nar\/gks818","article-title":"DNA repair endonuclease ERCC1\u2013XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy","volume":"40","author":"McNeil","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2020.112658_bib15","doi-asserted-by":"crossref","first-page":"11236","DOI":"10.1073\/pnas.0504341102","article-title":"Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF\u2013ERCC1","volume":"102","author":"Tsodikov","year":"2005","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2020.112658_bib16","doi-asserted-by":"crossref","first-page":"28644","DOI":"10.1074\/jbc.M501083200","article-title":"Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex","volume":"280","author":"Choi","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112658_bib17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/ijms19051328","article-title":"Computational characterization of small molecules binding to the human XPF active site and virtual screening to identify potential new DNA repair inhibitors targeting the ERCC1-XPF endonuclease","volume":"19","author":"Gentile","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112658_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jmgm.2016.02.010","article-title":"New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy","volume":"65","author":"Gentile","year":"2016","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2020.112658_bib19","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.2174\/1381612822666160420141435","article-title":"Modelling DNA repair pathways: recent advances and future directions","volume":"22","author":"Gentile","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.112658_bib20","doi-asserted-by":"crossref","first-page":"55246","DOI":"10.18632\/oncotarget.19422","article-title":"Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112658_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.dnarep.2015.04.002","article-title":"Inhibition of the ERCC1\u2013XPF structure-specific endonuclease to overcome cancer chemoresistance","volume":"31","author":"McNeil","year":"2015","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2020.112658_bib22","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1021\/acs.jmedchem.9b00326","article-title":"Targeting DNA repair in tumor cells via inhibition of ERCC1\u2013XPF","volume":"62","author":"Elmenoufy","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112658_bib23","first-page":"1","article-title":"Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction","author":"Gentile","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112658_bib24","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/bjc.2013.553","article-title":"A\u00a0phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer","volume":"109","author":"Kelley","year":"2013","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112658_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2018.12.028","article-title":"Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial","volume":"109","author":"Cremolini","year":"2019","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112658_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/nar\/gks284","article-title":"Fluorescence-based incision assay for human XPF\u2013ERCC1 activity identifies important elements of DNA junction recognition","volume":"40","author":"Bowles","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2020.112658_bib27","first-page":"1","article-title":"Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules","volume":"40","author":"Kourounakis","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112658_bib28","doi-asserted-by":"crossref","first-page":"16505","DOI":"10.1021\/bi048615m","article-title":"Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA","volume":"43","author":"Mani","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.112658_bib29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/ja01182a045","article-title":"The hydroxyethyl analog of quinacrine","volume":"70","author":"Carlson","year":"1948","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112658_bib30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00044-009-9209-5","article-title":"Aromatic amino analogues of artemisinin: synthesis and in\u00a0vivo antimalarial activity","volume":"19","author":"Sriram","year":"2010","journal-title":"Med. Chem. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420306309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420306309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:16:00Z","timestamp":1759328160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420306309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"alternative-id":["S0223523420306309"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112658","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and in\u00a0vitro cell-free\/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112658"}}